Toggle Menu



The Long Island Brain Tumor Center at Neurological Surgery, P.C.
Neuro-Oncology Research

The Long Island Brain Tumor Center at Neurological Surgery, P.C., is participating in the trials listed below.
To view additional information visit

For more information, please contact R. Kimberly Prabhu, MA, CCRP or Kerry McConie RN, OCN at (516) 478-0010

Newly Diagnosed Glioblastoma

  • Sponsor: Neurological Surgery, P.C.
    Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With
    Newly Diagnosed Glioblastoma (HBO)

Standard treatment for glioblastomas includes radiation and chemotherapy with a drug called temozolomide (Temodar); however, glioblastomas frequently develop resistance to standard treatment and recur or progress. Glioblastomas are known to have decreased levels of oxygen compared to normal tissues. There is evidence that these lower oxygen levels in glioblastomas may contribute to their ability to resist treatment effects of radiation and chemotherapy. In this study we will look to increase the oxygen concentration within the glioblastoma by adding hyperbaric treatments (the experimental part of this study) to standard treatment with radiation and temozolomide in order to see whether increasing the oxygen concentration within the tumor increases the tumor-killing ability of standard radiation and chemotherapy. 

  • Sponsor: Northwest Biotherapeutics
    A Phase III Clinical Trial Evaluating DCVax-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme

The purpose of the study is to determine the safety and efficacy of an investigational therapy called DCVax®-L in patients with newly diagnosed GBM for whom surgery is indicated. Patient must enter screening at a participating site prior to surgical resection of the tumor. Patients will receive standard of care, including radiation and Temodar therapy and two out of three will additionally receive DCVax®-L and the remaining one third will receive placebo. Patients randomized to placebo will have the option to receive DCVax®-L in a crossover arm upon documented disease progression. (note: DCVax®-L when used for patients with brain cancer is sometimes also referred to as DCVax-Brain)

  • Sponsor: ImmunoCellular Therapeutics, Ltd. (Closed for new enrollments)
    A Randomized, Double-Blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT 107 in Newly Diagnosed Patients with Glioblastoma Multiforme Following Resection and Chemoradiation

This is a Phase II, multicenter study to determine the safety and efficacy of ICT-107 in treating a type of brain tumor called glioblastoma multiforme (GBM). ICT-107 is an immunotherapy in which the patient's immune response will be stimulated to kill the tumor cells. Patients must be newly diagnosed with GBM and not yet received chemoradiation. Some of the patient's white blood cells (WBC) will be removed and cultured in a laboratory with purified antigens, similar to those on GBM cells. The patient's own WBC/DC that have been exposed to the tumor antigens will then be given back to the patient as a vaccine over several months. The goal is for the ICT-107 vaccine to stimulate the patient's immune response to kill the remaining GBM tumor cells after surgery and chemotherapy.

  • Sponsor: Celldex Therapeutics CDX110-04 (Closed for new enrollments)
    An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-Positive Glioblastoma(The “ACT IV” Study)

This 2-arm, randomized, Phase III study will investigate the efficacy and safety of the addition of rindopepimut (an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have tumors that express the EGFRvIII protein) to the current standard of care (temozolomide) in patients with recently diagnosed glioblastoma, a type of brain cancer.  All patients will be administered temozolomide, the standard treatment for glioblastoma. Half the patients will be randomly assigned to receive rindopepimut and half the patients will be randomly assigned to receive a control called keyhole limpet hemocyanin.  Patients will be treated in a blinded fashion (neither the patient or the doctor will know which arm of the study the patient is on). Patients will be treated until disease progression or intolerance to therapy and all patients will be followed for survival.

Recurrent Glioblastoma

  • Sponsor: AbbVie, Inc.
    ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group

    This study is to evaluate the efficacy and safety of ABT-414 alone or with temozolomide versus temozolomide or lomustine alone in participants with recurrent glioblastoma multiforme.
  • Sponsor: Nativis, Inc.
    A Feasibility Study of the Nativis Voyager System in Patients With Recurrent Glioblastoma Multiforme (GBM)

    This feasibility study will assess the effects of the Nativis Voyager therapy in patients with recurrent GBM who have either failed standard of care or are intolerant to therapy. The study will enroll and treat up to eleven subjects over six months. Safety and clinical utility will be evaluated.
  • Sponsor:  Cortice Biosciences, Inc
    Phase II Dose-Escalation Study of TPI 287 in Combination with Bevacizumab in Adults with Recurrent Glioblastoma Safety and Efficacy Study of TPI 287 in Combination With Avastin (Bevacizumab) to Treat Glioblastoma

The purpose of this study is to determine the safety, maximum tolerated dose (MTD), and efficacy of TPI 287 in combination with Avastin (bevacizumab) in subjects who have glioblastoma multiforme (GBM) that has recurred or progressed following prior radiation therapy and temozolomide (TMZ).

  • Sponsor: Celldex Therapeutics CDX110-06 (Closed for new enrollments)
    A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma

The purpose of this research study is to find out whether adding an experimental vaccine called rindopepimut (also known as CDX-110) to the commonly used drug bevacizumab can improve progression free survival (slowing the growth of tumors) of patients with relapsed EGFRvIII positive glioblastoma.

Recurrent Brain Metastases

  • Sponsor:  Angiochem Inc.
    A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients with Recurrent Brain Metastases.

This is a Phase II study to see if an investigational drug, ANG1005, can shrink tumor cells in breast cancer patients with recurrent brain metastases. Study Center Locations:

Expanded Access

  • Sponsor:  Northwest Biotherapeutics
    An Expanded Access Protocol for the Treatment of Glioblastoma Multiforme in Patients with Already Manufactured DCVax®-L, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen Who Have Screen-Failed Protocol 020221

The study is an open-label expanded access study for patients for whom vaccine was manufactured during the Northwest Biotherapeutics' 020221 DCVax®-L for GBM screening process, but who subsequently failed to meet specific enrollment criteria. Patients will receive therapy per investigator discretion (standard of care) as well as active vaccine per the 020221 protocol administration schedule. It is estimated that approximately 99 patients will enroll in this study.   

  • Sponsor: Celldex Therapeutics, Inc CDX110-05

The study is an open-label expanded access study for patients who do not qualify for Celldex currently enrolling studies.


(800) 775-7784 | (516) 300-1281

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon
Join our Email
Mailing List